Last reviewed · How we verify
Rivastigmine Transdermal System
At a glance
| Generic name | Rivastigmine Transdermal System |
|---|---|
| Sponsor | Yale University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Rivastigmine Transdermal Patches Bioequivalence and Adhesion Assessment (PHASE1)
- CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease) (PHASE3)
- Toward a Computationally-Informed, Personalized Treatment for Hallucinations (EARLY_PHASE1)
- A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease (PHASE3)
- A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type. (PHASE4)
- Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease (PHASE4)
- Telerehabilitation Alzheimer's Disease Feasibility (TADF) (NA)
- Effect of Heat on Rivastigmine TDS Products (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rivastigmine Transdermal System CI brief — competitive landscape report
- Rivastigmine Transdermal System updates RSS · CI watch RSS
- Yale University portfolio CI